Wacker Biosolutions to focus on biotechnology

Published: 2-Mar-2010
Manufacturing Ingredients Finance Pharmaceutical

Wacker Fine Chemicals becomes Wacker Biosolutions and concentrates on biotechnology

Wacker, the German chemical company, has changed the name of its Wacker Fine Chemicals division to Wacker Biosolutions as it gives the business a biotechnology focus.

Wacker Biosolutions will concentrate on building its business in three main areas, including pharmaceuticals, alongside its existing portfolio of fine chemicals and chemical intermediates. Its biotech products include cyclodextrins, cysteine and biologics, as well as fine chemicals and PVAc solid resins.

The Munich-based firm is currently extending process development and production capacities for the manufacture of pharmaceutical proteins at Wacker Biotech in Jena, Germany.

Wacker aims to offer tailored complete solutions to customers, taking advantage of the synergies between its chemical and biotech expertise. It sees potential in providing innovative products and technologies in the budding market for bioengineered products.

"This reorganisation lays further foundations for Wacker's future success in the growing field of biotechnology," said Gerhard Schmid, senior vice president of Wacker Biosolutions.

Over the past few years, Wacker has posted high double-digit growth with biotech products such as cyclodextrins and cysteine. The group sees future global-market potential in pharmaceutical actives, food additives and agrochemicals.

See more

You may also like

Finance

Shilpa Medicare opens flow chemistry manufacturing centre

Read more
The flow chemistry centre of excellence includes more than 100 R&D and manufacturing scientists

Trending Articles

  1. Touchlight named most innovative new manufacturing facility at ISPE 2025 Facility of the Year Awards The company’s restored Victorian waterworks site in Hampton, London, has been recognised for transforming DNA manufacturing with its enzymatic, cell-free dbDNA platform
  2. Amphista Therapeutics nominates first clinical candidate AMX-883, a novel Targeted Glue degrader for acute myeloid leukaemia AMX-883, an orally available BRD9 degrader developed using Amphista’s Eclipsys platform, shows potent preclinical efficacy and a distinct DCAF16-based mechanism of action, paving the way for first-in-human trials in 2026
  3. Aseptic spray drying: Transforming biotherapeutics for a new era With interest in aseptic spray drying on the rise in the pharmaceutical industry, Dr Kevin Robinson spoke to GEA’s David Costes about how the company is combining process, engineering and technological expertise with market insights to provide a safe, reliable and high-performance technology for advanced biotherapeutic powder applications
  4. ACG to invest $200m in US hard-shell capsule manufacturing ACG will build its first US capsule manufacturing facility in Atlanta, Georgia, with dedicated gelatine and HPMC lines, creating more than 200 jobs and expanding its North American presence ahead of operations starting in early 2027
  5. Takeda and Innovent Biologics partner to advance next-gen oncology medicines Takeda will establish manufacturing of two next-generation late-stage investigational medicines in the US and will receive exclusive commercialisation rights for IBI363 and IBI343 outside the US and China

You may also like

Finance

Shilpa Medicare opens flow chemistry manufacturing centre

The flow chemistry centre of excellence includes more than 100 R&D and manufacturing scientists
Manufacturing

Frontline innovation: dispatches from the show floor at CPHI Frankfurt (part III)

The third instalment from the CPHI Frankfurt show floor explores practical approaches and fresh perspectives on scale-up, tech transfer, and manufacturing innovation across the pharmaceutical sector
Manufacturing

Streamlining bioconjugation for next-generation ADC development

Abzena’s proprietary ThioBridge™ technology delivers precision, scalability, and enhanced stability for antibody-drug conjugates
Manufacturing

OPTIMA machinery USA Corporation marks 40 years of growth and innovation in the US

OPTIMA machinery USA Corporation, a subsidiary of the German-based OPTIMA Packaging Group, is celebrating 40 years of successful operations in the United States
Manufacturing

How to execute a successful remediation strategy

NSF’s experts share guidance on building sustainable compliance and avoiding quick fixes
Manufacturing

How to optimise your quality culture and maturity for success

NSF outlines how aligning culture, leadership and systems can strengthen compliance and performance
Manufacturing

Frontline innovation: dispatches from the show floor at CPHI Frankfurt (part II)

Industry leaders at CPHI Frankfurt are embracing emerging technologies — including automation, AI, advanced analytics and innovative manufacturing platforms — to drive efficiency, quality, scalability and sustainability in pharmaceutical production and development
Subscribe now